The estimated Net Worth of John L Lubniewski is at least $1.23 Миллион dollars as of 1 April 2016. Mr. Lubniewski owns over 796 units of HTG Molecular Diagnostics Inc stock worth over $12,013 and over the last 10 years he sold HTGM stock worth over $59,273. In addition, he makes $1,157,740 as President, Chief Executive Officer и Director at HTG Molecular Diagnostics Inc.
Sign up
Mr. Lubniewski HTGM stock SEC Form 4 insiders trading
John has made over 7 trades of the HTG Molecular Diagnostics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 796 units of HTGM stock worth $2,300 on 1 April 2016.
The largest trade he's ever made was selling 6,889 units of HTG Molecular Diagnostics Inc stock on 10 March 2016 worth over $16,396. On average, John trades about 548 units every 5 days since 2015. As of 1 April 2016 he still owns at least 25,027 units of HTG Molecular Diagnostics Inc stock.
You can see the complete history of Mr. Lubniewski stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
John Lubniewski biography
John L. Lubniewski serves as President, Chief Executive Officer, Director of the Company. Mr. Lubniewski joined us from Ventana, a medical diagnostics company and member of the Roche Group and global headquarters of Roche Tissue Diagnostics (“RTD”) where he served in leadership roles for nine years both before and after the acquisition of Ventana by Roche in March 2008. From August 2010 to April 2011, Mr. Lubniewski was Senior Vice President and Lifecycle Leader, Advanced Staining Platforms at Ventana. From January 2008 to August 2010, Mr. Lubniewski served as Senior Vice President and Lifecycle Leader, Clinical Assays at RTD, with responsibility for three lifecycle teams, technical marketing and medical marketing and global accountability for all RTD clinical assay products. Prior to the Roche acquisition of Ventana, Mr. Lubniewski served at Ventana as Senior Vice President, Advanced Staining Business Unit, Vice President Worldwide Marketing and Translational Diagnostic Business Unit, and General Manager, Research Products. In these roles, Mr. Lubniewski was responsible for a variety of assay and platform development and commercialization efforts. Prior to Ventana, Mr. Lubniewski worked for over ten years at Corning, Inc., a manufacturing company, in a variety of divisional, sector and corporate sales and marketing roles. Mr. Lubniewski earned a B.S. in Chemical Engineering from Clarkson University.
What is the salary of John Lubniewski?
As the President, Chief Executive Officer и Director of HTG Molecular Diagnostics Inc, the total compensation of John Lubniewski at HTG Molecular Diagnostics Inc is $1,157,740. There are no executives at HTG Molecular Diagnostics Inc getting paid more.
How old is John Lubniewski?
John Lubniewski is 56, he's been the President, Chief Executive Officer и Director of HTG Molecular Diagnostics Inc since 2019. There are 12 older and 4 younger executives at HTG Molecular Diagnostics Inc. The oldest executive at HTG Molecular Diagnostics Inc is Harry George, 71, who is the Independent Director.
What's John Lubniewski's mailing address?
John's mailing address filed with the SEC is C/O HTG MOLECULAR DIAGNOSTICS, INC., 3430 E. GLOBAL LOOP, TUCSON, AZ, 85706.
Insiders trading at HTG Molecular Diagnostics Inc
Over the last 10 years, insiders at HTG Molecular Diagnostics Inc have traded over $5,630,772 worth of HTG Molecular Diagnostics Inc stock and bought 1,019,150 units worth $14,128,765 . The most active insiders traders include Plc Gsk, Holdings A/S Novo и Laurence W Lytton. On average, HTG Molecular Diagnostics Inc executives and independent directors trade stock every 64 days with the average trade being worth of $28,039. The most recent stock trade was executed by Stephen Barat on 8 June 2023, trading 888 units of HTGM stock currently worth $710.
What does HTG Molecular Diagnostics Inc do?
about htg molecular diagnostics: headquartered in tucson, arizona, htg's mission is to empower precision medicine at the local level. in 2013 the company commercialized its htg edge instrument platform and a portfolio of rna assays that leverage htg's proprietary nuclease protection chemistry. htg's product offerings have since expanded to include its htg edgeseq product line, which automates sample and targeted library preparation for next-generation sequencing. additional information is available at www.htgmolecular.com.
What does HTG Molecular Diagnostics Inc's logo look like?
Complete history of Mr. Lubniewski stock trades at HTG Molecular Diagnostics Inc
HTG Molecular Diagnostics Inc executives and stock owners
HTG Molecular Diagnostics Inc executives and other stock owners filed with the SEC include:
-
John Lubniewski,
President, Chief Executive Officer, Director -
John L. Lubniewski,
Pres, CEO & Director -
Shaun D. McMeans,
Sr. VP, CFO, Sec. & Treasurer -
Shaun McMeans,
Chief Financial Officer, Senior Vice President, Treasurer, Secretary -
Byron T. Lawson,
Sr. VP & Chief Commercial Officer -
Timothy Johnson,
Executive Chairman of the Board -
Byron Lawson,
Senior Vice President and Chief Commercial Financial Officer -
Lee McCracken,
Independent Director -
James LaFrance,
Independent Director -
Donnie Hardison,
Independent Director -
Michelle Griffin,
Independent Director -
Harry George,
Independent Director -
Ann Hanham,
Lead Independent Director -
Laura Beggrow,
Pres of Diagnostics -
Dr. Stephen A. Barat Ph.D.,
Sr. VP of Therapeutics -
Dr. Marian Navratil Ph.D.,
Sr. VP of R&D -
Dr. Patrick C. Roche,
Sr. VP of R&D -
Dr. Debra A. Gordon,
Sr. VP & Chief Legal Counsel -
Laura Lee Godlewski,
Sr. VP of Fin. & Admin. -
Dr. Maureen T. Cronin Ph.D.,
Sr. VP & Chief Scientific Officer -
Christopher P Kiritsy,
Director -
Stephen Barat,
Senior VP of Therapeutics -
Debra A Gordon,
V.P. and Chief Legal Counsel -
Lewis Shuster,
Director -
Plc Gsk,
10% owner -
Don M Hardison,
Director -
Holdings A/S Novo,
10% owner -
Nv Qiagen,
10% owner -
Patrick C. Roche,
SVP Research & Development -
Spaght Ventures Ii Lpfsv Ii...,
-
Donald W Grimm,
Director -
Capital Ventures Llc Senour...,
-
Tim B Johnson,
Executive Chairman -
Laurence W Lytton,
10% owner -
Thomas W. Dubensky,
Director -
Laura Lee Godlewski,
SVP Finance & Administration